<DOC>
	<DOCNO>NCT02666651</DOCNO>
	<brief_summary>Low blood sodium common observation patient present heart failure associate increased mortality , prolong hospital stay , repeat hospital visit . Tolvaptan new approve medication treat low sodium level patient present symptom heart failure , however , currently available treatment option due high cost cover provincial plan . In observational , non-randomized study drug provide subject free charge give hospital stay . After discharge subject follow 6 month ( 3 visit ) .</brief_summary>
	<brief_title>Regional Tolvaptan Registry</brief_title>
	<detailed_description>Purpose : A prospective , open-label , real life registry Tolvaptan hospitalize heart failure patient hyponatremia . Hypothesis : Administration Tolvaptan hospitalize patient heart failure hyponatremia demonstrate improvement patient symptom status cost saving decrease healthcare utilization . Justification : In clinical trial , Tolvaptan show quickly , effectively , safely improve sodium level heart failure patient , decrease length hospital stay improve symptom status compare placebo . Although Tolvaptan approve drug Canada treatment patient hospitalize heart failure hyponatremia , availability limited private buyer available hospital formulary due cost constraint . There alternative first class agent . Objectives : The primary endpoint reduction length stay heart failure registry participant compare length stay Vancouver Coastal Health ( VCH ) administrative data set . Secondary endpoint include recurrent hospitalization , change quality life , B-type Natriuretic Peptide ( BNP ) level study period . Research Method : Patients admit Vancouver General Hospital ( VGH ) heart failure hyponatremia identify clinical referral cardiologist ensure measure undertaken improve patient 's clinical status . Tolvaptan dispense accord product monograph clinician discretion , discontinue serum sodium normalize , case drug relate adverse event hospital discharge . Bloodwork drawn monitor liver function electrolytes hospitalization follow . Data capture time consent 6 month hospital discharge .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Patient clinical evidence heart failure AND elevate BNP evidence leave ventricular dysfunction ( left ventricular ejection fraction ( LVEF ) &lt; 40 % ) diagnostic imaging . 2 . Serum sodium &lt; 130 mmol/L OR serum sodium 131134 mmol/L symptomatic . 3 . Sodium fluid restriction ongoing . 4 . Trial optimal diuretic therapy ( prescribe physician 's clinical discretion ) . 5 . Discontinuation nonessential medications/treatments know cause hyponatremia . 1 . Life expectancy &lt; 6 month 2 . Documented adverse event tolvaptan past 3 . Meet exclusion criterion Study Ascending Levels Tolvaptan Hyponatremia ( SALT Trial ) : Serum sodium &lt; 120mmol/L neurologic impairment Confounding disease ( e.g . recent stroke myocardial infarction ( MI ) , recent surgery , uncontrolled diabetes , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>